# Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin

> **NCT01770392** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 26 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Rifampicin
- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT01770392
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2014-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01770392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01770392, "Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01770392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*